Johnson & Johnson gearing up (NYSE:JNJ)

The world’s biggest healthcare company, Johnson & Johnson has stated that currently they are waiting for the approval of their new products. On a Tuesday morning, the world’s premier health company provided more information about the earnings for the third quarter. Many trade analysts have speculated that the shares of Johnson & Johnson might move up quickly once the new products are being approved that are currently in line up with the health regulators. The company is already a leading brand name when it comes to Band-Aids, No More Tears shampoo and Acuvue contact lenses. Now with new products under the belt, Johnson and Johnson is simply trying to drive the sales figures upwards even during the global recession.

Additionally, the company has made four significant deals in the last quarter of 2009, in which it clearly shows that Johnson & Johnson is now trying to enter the vaccines business too. Johnson & Johnson has paid US$ 440 million to the Dutch biotechnology company named Crucell NV which develops anti-body-based vaccines and drugs that target all kinds of influenza. The company has also invested in an Irish biotech company, Elan Corp, which will help J&J to develop two experimental drugs for Alzheimer’s disease and a vaccine to prevent it.

To add more to company’s line of mergers, Johnson & Johnson has completed a US$ 894 million acquisition with Cougar Biotechnology which will help them with potential treatment testing for prostrate cancer. And another partnership deal with Gilead Sciences Inc, which will help J&J to come out with a single daily HIV pill that will help AIDS patients to avoid consuming multiple tablets

Currently, J&J is awaiting for approval from the Food and Drug Administration panel for its Pinnacle Complete hip implant system. Other products include Xarelto and Comfyde that are still under FDA review.